Advanced Enzyme Technologies Limited has informed the Exchange regarding a press release dated May 13, 2025, titled "Quarterly Earnings Release dated May 13, 2025".
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Advanced Enzyme Technologies announced its Q4 FY25 and full-year FY25 results on May 13, 2025. Q4 FY25 revenue grew 6% year-on-year to ₹1,672 million, but EBITDA fell 18% to ₹456 million and profit after tax declined 11% to ₹267 million, with EPS at ₹2.37. For the full year FY25, revenue rose 2% to ₹6,369 million, EBITDA dropped 5% to ₹1,944 million, and PAT slipped 2% to ₹1,340 million, translating to an EPS of ₹11.72. Margins compressed meaningfully, with Q4 EBITDA margin falling to 27% from 35% a year ago and full-year margin easing to 31% from 33%. Internationally, revenue grew 11% to ₹3,464 million (now 54% of sales), while domestic revenue fell 6%; Specialized Manufacturing surged 30% for the year, but the core Human Nutrition segment declined 3%.
Mixed bag for shareholders — top-line growth is intact, but profit, margin compression, and a weak domestic performance may weigh on sentiment, even as international and Specialized Manufacturing segments show strength. A conference call is scheduled for May 14, 2025, which could shape near-term stock direction.